Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The new approval makes the regimen an option for around 4,000 patients in the EU who have at least one non-class I CFTR mutation.

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

Dr. Michael Welsh, a longtime University of Iowa physician-scientist, has been named a 2025 recipient of the prestigious ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF ... a groundbreaking treatment for sickle cell disease patients. This one-time, gene-edited cell therapy, developed with ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination ...

Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted regulatory approval for a label expansion of KAFTRIO in a ...